Fallopian tube cancer

• The assessment of bevacizumab dose equivalence in ovarian cancer Pending
  2023-509659-15-00 6 "Patients with ovarian cancer, fallopian tube cancer, periton"
• A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications Recruiting
  2023-506227-29-00 3 2024-08-30 "locally advanced or metastatic solid tumors"
• Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s … Recruiting
  2022-501606-35-01 11 2024-02-21 "Platinum-sensitive epithelial ovarian, fallopian tube, or pr"
• Evaluation of epithelial ovarian, primary peritoneal, or fallopian tube cancer treatment in first recurrance using platinum-based chemothera … Recruiting
  2022-501220-14-00 4 2023-10-17 "epithelial ovarian, primary peritoneal, or fallopian tube ca"
• Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose … Recruiting
  2024-516066-11-00 5 2022-08-31 "Patients with newly diagnosed, histologically confirmed, pri"
• A trial to learn how safe AZD5335 is and if a drug called itraconazole changes how AZD5335 moves through the body over time in adults with o … Recruiting
  2025-522731-34-00 3 2026-01-23 "Ovarian cancer Primary peritoneal cancer Fallopian tube canc"
• A study to evaluate dosing schedules of mirvetuximab soravtansine in patients with epithelial ovarian, primary peritoneal, or fallopian tube … Recruiting
  2024-517184-23-00 4 2025-10-16 "platinum-resistant advanced high-grade epithelial ovarian, p"
• An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting
  2024-517432-21-00 4 2025-05-30 "Gynecological Cancers"
• N-PLUS Recruiting
  2022-502559-69-01 4 2024-07-04 "advanced (FIGO stage IIIA, IIIB, IIIC, or IV of the 2014 FIG"
• A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Can … Recruiting
  2023-507914-28-00 10 2024-06-19 "Platinum-resistant, high-grade serous ovarian cancer (OVC),h"
• Trial to Better Characterize the Status of HRD leading to a Benefit from Olaparib in Combination with Bevacizumab in Patients with Advanced … Recruiting
  2024-517363-24-00 4 2024-02-16 "Advanced FIGO Stage III‐IV High Grade Serous or Endometrioid"
• A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given with Either Cemiplimab, or Cemiplimab + Fianlimab, … Recruiting
  2022-501904-83-00 7 2023-09-11 "Ovarian Cancer"
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 "BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian can"
• Study of REGN4018 (Ubamatamab) Administered Alone or in Combination with Cemiplimab in Adult Patients with Recurrent Ovarian Cancer or Other … Recruiting
  2024-510783-23-00 7 2020-10-29 "Fallopian Tube Cancer"
• First trial in humans testing the safety and efficacy of IMGN151 in women with recurrent gynaecological cancers Recruitment ended
  2023-506842-22-00 7 2025-05-19 "Recurrent endometrial cancer, recurrent epithelial ovarian, "
• A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Recruitment ended
  2024-514080-25-00 5 2023-04-21 "Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian,"
• PERCEPTION Recruitment ended
  2023-508155-40-00 4 2022-01-25 "recurrent platin sensitive low-grade serous ovarian-, fallop"
• A randomized phase II trial of Mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα) high recurrent ovarian cancer eligible fo … Recruitment ended
  2024-516959-40-00 4 2021-08-17 "This trial evaluates the efficacy and safety of Mirvetuximab"
• Comparing Paclitaxel-Carboplatin-Oregovomab versus Paclitaxel-Carboplatin-Placebo in Patients with Advanced Ovarian Cancer Recruitment ended
  2024-519218-30-00 5 2021-05-26 "Advanced epithelial ovarian, fallopian tube or peritoneal ca"
• MITO 25.1: A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucapar … Recruitment ended
  2024-516632-99-00 4 2021-03-17 "Advanced (stage III B-C-IV) ovarian, primary peritoneal and "
• Phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer considering two different … Recruitment ended
  2024-514706-31-01 5 2019-05-02 "Epithelial ovarian cancer, Fallopian tube ovarian cancer, Pe"
• A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Bas … Recruitment ended
  2024-516662-11-00 5 2018-11-23 "Ovarian epithelial cancer"
• A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Ended
  2023-504111-33-00 4 2023-02-14 "Platinum-resistant High-grade Serous Ovarian, Primary Perito"
• Study of Nemvaleukin Alfa in Combination with Pembrolizumab Versus Investigator's Choice Chemotherapy in Patients with Platinum-Resistant Ep … Ended
  2024-513230-38-00 5 2022-12-15 "Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Pr"

Showing 1–24 of 27 trials